First, Joe does say it correctly once, but our study compared the risk we identified via VAERS of post-vaccination myocarditis (1/6200 in 12-15 yo boys and 1/10,600 in 16-17 yo boys) to the risk of hospitalization over the next *4 months* and *not overall* from COVID-19.
We did find that, even at times of high disease prevalence, that boys 12-17 without medical comorbidities were more likely to have post vax myocarditis after dose 2 than be hospitalized for COVID (over a 120-day period)
It is correct that the hospitalization rate we identified in those with myocarditis was around 84%. Israel found an 81% hospitalization rate among their myocarditis cases; most cases mild, but one death. nejm.org/doi/full/10.10…
What was not discussed on the show was other reports finding *higher* rates of myocarditis in this demographic than we found, for example Israel (1/6600 for 16-19 yo males) and Ontario (1/5600)
Ontario Canada has is reporting the highest rates (1/5600 for 12-17 yo males). So our study's post-vax myo rates in boys after dose 2 are well in line with other studies (in fact our rates were lower)
The above studies were of Pfizer, but Moderna seems to have an rate of post-vax myocarditis in young men (Scandinavian data for young men; not yet released for boys) & Nordic countries pausing Moderna in this demographic for this reason
The ? of the rate of COVID myocarditis in this age group is a good one. Unfortunately we don't have good data yet. We have good data on asympt & symptomatic covid-related myocarditis in college aged men, but not boys due to inappropriate denominator ⬇️
Our study & others have brought up more questions than answers: What is the benefit of vaccinating a previously infected child? Would it be reasonable for boys just receive 1 dose of vaccination who have not been prev infected? How often do long-term sequelae develop from this?
I'm grateful that @joerogan and @drsanjaygupta found this topic worthy of discussion -pls more discussions like this! I think every one of us wants to work together to minimize harm & do the right thing for our kids. P.S. I'm pro vax & double vaccinated myself & grateful for it.
In the revision of our pre-print, we are taking into consideration 1. overall infection hospitalization rate, 2. the benefits of one dose of the vaccine and 3. a history of natural infection. TY team: @drjohnm , @KrugAlli@ifihadastick
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The Nordic data on the frequency of myocarditis after dose 2 of Moderna (Spikevax) in 18-29 year old men have been released: 1/4,800.
For Pfizer, it's 1/25,000. fhi.no/nyheter/2021/m…
>5x difference, but see data from Ontario below (1/5)
Ontario rate is now 1/5600 (mostly Pfizer) in boys 12-17
My ?: Is some of the increase in frequency simply due to awareness of condition? (in addition to increased Moderna use?) 2/5
- Israel rate from NEJM 1/6600 for 16-19 yo (Pfizer) nejm.org/doi/full/10.10…
(For ref our VAERS pre-print: 1/6200 in 12-15 yo males, 1/10,600 in 16-17 yo (Pfizer))
Reports taken together point to ⬆️ rate in younger boys & after Moderna & ⬆️ awareness of this condition 3/5
The Israeli @nejm study published today that stratified for myocarditis rates post vax dose 2 in males age 16-19 found a rate of 1/6600 for Pfizer. Our preprint found a *lower* rate of 1/10,600 for 16-17 yo males. For 12-15 yo males we found 1/6200 nejm.org/doi/full/10.10…
I'm really grateful for this NEJM study⬆️ & glad to see our VAERS-based study didn't provide an overestimate in 16-17 yo males. This was as expected with VAERS typically underreporting. I hope more studies are published with 12-15 year old estimated rates. medrxiv.org/content/10.110…
From second NEJM study "Most cases of myocarditis were of mild or intermediate severity" "1 patient had cardiogenic shock, & 1 patient w/preexisting cardiac disease died of an unknown cause after.. discharge Left ventricular dysfunction in 29% of patients" nejm.org/doi/full/10.10…
MMWR AZ 🌵 mask study #1 limitation:
-Not adjusting for community cases in Maricopa Co (R) rising more during the study (see Figures)
-They adjusted for pre-study case rates, but that was not enough
-remember ~ 95% of school cases come from the community! cdc.gov/mmwr/volumes/7…
Maricopa also had a lower vaccination rates: 47.6% vs 59.2% in Pima.
Likely the entire story here is more school cases in schools w/o mask mandates (mostly in Maricopa) due to higher comm. case rates related to lower vax rates. How did this become a mask story?🤔
Since I am literally sitting on the side of a soccer field in Stockton, for further info, I want to refer you to @VPrasadMDMPH 's discussion of these two MMWR studies & why we unfortunately can't learn about the effectiveness of masks from them. vinayprasadmdmph.substack.com/p/two-new-cdc-…
I want to answer 2 questions we are frequently receiving about our study (which are excellent questions!): 1. Why did you use 120-day COVID hospitalization risk rather than overall COVID hospitalization risk? 2. But isn't post COVID myo *more* common than post-vax myo? 1/
2/ The US infection-hospitalization risk in the peds population is too uncertain bc we don't have reliable seroprevalence numbers. Based on a v recent analysis of UK data there is about a 1/750 chance for a child to be hospitalized/infection. TY @apsmunro
3/ We used 120-day hospitalization/population (just as the CDC did in their analysis) because there was less uncertainty about its accuracy. It also allowed us to include multiple rates in our model & incl. recent delta rates, as shown below from COVID-NET gis.cdc.gov/grasp/covidnet…
It's important to note, it's the CDC's estimates of myocarditis in boys & young men that have been the outliers. Israel & Canada reporting similar rates of post-vax myo to the 1/6,000 from our study. TY @_lewisy for the Israeli data ⬇️ medrxiv.org/content/10.110…
Our group's analysis of pediatric post-vax myocarditis rates stratified by age, sex & dose. An extensive harm-benefit analysis is included w/consideration of presence or absence of comorbidities
"For boys 12-17 without medical comorbidities, the likelihood of post vax dose 2 CAE is 162.2 & 94.0/million respectively. This... exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) & high COVID-19 hospitalization incidence"
I agree with @DrJBhattacharya highlighting @adamhfinn of JCVI here stating how cautious we need to be with our vaccination recommenations in this low risk group
Personal bias: I am a mom of 10 and 13 year old boys & want the best for them & all kids